Atypical Parkinsonism

Overview

Atypical parkinsonism refers to a group of neurodegenerative disorders that present with parkinsonian features (bradykinesia, rigidity, tremor) but differ from idiopathic Parkinson’s disease (PD) in their pathophysiology, clinical presentation, prognosis, and response to treatment^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}. These disorders are also known as “Parkinson-plus syndromes” and include Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB)^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}.

Unlike idiopathic PD, which is primarily a dopaminergic disorder affecting the substantia nigra pars compacta, atypical parkinsonian disorders involve multiple neurotransmitter systems and have distinctive pathological features. Accurate differentiation is critical for prognosis, clinical trial enrollment, and emerging disease-modifying therapies.

Disease Classification

flowchart TD
    A["Atypical Parkinsonism<br/>(Parkinson-Plus)"] --> B["alpha-Synucleinopathies"]
    A --> C["Tauopathies"]

    B --> D["MSA-P<br/>Multiple System Atrophy<br/>Parkinsonian Type"]
    B --> E["MSA-C<br/>Multiple System Atrophy<br/>Cerebellar Type"]
    B --> F["DLB<br/>Dementia with<br/>Lewy Bodies"]

    C --> G["PSP<br/>Progressive<br/>Supranuclear Palsy"]
    C --> H["CBS<br/>Corticobasal<br/>Syndrome"]
    C --> I["FTLD-tau<br/>Frontotemporal Lobar<br/>Degeneration"]

    D --> J["Autonomic Failure<br/>Cerebellar Signs"]
    G --> K["Vertical Gaze Palsy<br/>Postural Instability"]
    H --> L["Asymmetric Rigidity<br/>Alien Limb / Apraxia"]
    F --> M["Visual Hallucinations<br/>Cognitive Fluctuations"]

    style A fill:#006494,color:#e0e0e0
    style B fill:#4a1a6b,color:#e0e0e0
    style C fill:#6d3b00,color:#e0e0e0
    style G fill:#6d3000,color:#e0e0e0
    style H fill:#6d3000,color:#e0e0e0

Classification of Atypical Parkinsonian Disorders

Primary Atypical Parkinsonism Disorders

Secondary Causes of Atypical Parkinsonism

• Vascular Parkinsonism: Multi-infarct disease affecting basal ganglia

• Drug-induced parkinsonism: Antipsychotics, antiemetics

• Normal pressure hydrocephalus: Gait disturbance, urinary incontinence, dementia

• Neurodegeneration with Brain Iron Accumulation (NBIA): Pantothenate kinase deficiency

Clinical Features Distinguishing Atypical Parkinsonism from PD

Red Flags for Atypical Parkinsonism

The following clinical features should raise suspicion for an atypical disorder^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}:

1. Early falls: Within the first year of symptom onset

2. Vertical gaze palsy: Particularly downward gaze

3. Early autonomic dysfunction: Orthostatic hypotension, urinary urgency

4. Cerebellar signs: Ataxia, nystagmus, dysmetria

5. Cortical sensory loss: Two-point discrimination, stereognosis

6. Apraxia: Inability to perform learned movements on command

7. Alien limb phenomenon: Feeling that a limb is foreign

8. Dystonia: Early-onset, particularly axial

9. Poor levodopa response: Minimal or transient benefit

10. Rapid progression: Disability within 3-5 years

Feature Comparison Table

Progressive Supranuclear Palsy (PSP)

Clinical Variants

PSP presents in multiple clinical phenotypes beyond the classic Richardson syndrome^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}:

• PSP-Richardson (PSP-RS): Classic presentation with vertical gaze palsy, falls, postural instability

• PSP-Parkinsonism (PSP-P): Parkinsonism dominant, may be mistaken for PD

• PSP-Pure Akinesia with Gait Freezing (PSP-PAGF): Gait freezing without gaze palsy

• PSP-Cerebellar (PSP-C): Predominant cerebellar ataxia

• PSP-Primary Cortical Gaze Palsy (PSP-PCGP): Oculomotor predominant

• CBS/PSP overlap: Features of both disorders

Pathological Features

• 4R tau accumulation: Predominant 4-repeat tau isoforms

• Neurofibrillary tangles: In brainstem, basal ganglia

• Tufted astrocytes: Pathognomonic for PSP

• Globose degeneration: In subcortical nuclei

Diagnostic Criteria

NINDS-SPSP Criteria (adapted):

Definite PSP: Clinical history + neuropathological confirmation

Probable PSP:

• Vertical supranuclear gaze palsy + postural instability with falls within first year

• Or vertical supranuclear gaze palsy + progressive akinesia and rigidity

Possible PSP:

• At least two of: vertical gaze palsy, postural instability, akinesia

• Plus at least one of: frontal dysfunction, subcortical dementia

Corticobasal Syndrome (CBS)

Clinical Features

CBS is characterized by asymmetric parkinsonism with cortical dysfunction^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}:

• Apraxia: Most common cortical sign; affects hand use

• Alien limb: Feeling that limb is not under one’s control

• Cortical sensory loss: Impaired two-point discrimination, stereognosis

• Alien hand syndrome: Involuntary motor activity

• Progressive aphasia: Language difficulties

Motor Features

• Akinesia and rigidity: Asymmetric onset, often in dominant hand

• Dystonia: Often early, focal, and task-specific

• Myoclonus: Cortical origin, stimulus-sensitive

• Levodopa response: Usually poor

Pathological Features

• 4R tauopathy: Neuronal and glial inclusions

• Asymmetric cortical atrophy: Particularly frontoparietal regions

• Basal ganglia degeneration: Globus pallidus, substantia nigra

Multiple System Atrophy (MSA)

Clinical Subtypes

• MSA-Parkinsonism (MSA-P): Parkinsonism dominant

• MSA-Cerebellar (MSA-C): Cerebellar ataxia dominant

Core Clinical Features

• Autonomic dysfunction: Orthostatic hypotension, urinary dysfunction

• Cerebellar signs: Ataxia, scanning speech, nystagmus

• Parkinsonism: Bradykinesia, rigidity, tremor

• Pyramidal signs: Hyperreflexia, Babinski sign

Pathological Features

• α-Synuclein inclusions: Glial cytoplasmic inclusions (GCIs)

• Olivopontocerebellar atrophy: Brainstem and cerebellar degeneration

• Striatonigral degeneration: Dopaminergic neuron loss

Diagnostic Criteria

Consensus Criteria (2008):

Definite MSA: Neuropathological confirmation

Probable MSA: Autonomic failure + parkinsonism OR autonomic failure + cerebellar syndrome

Possible MSA: Parkinsonism or cerebellar syndrome + at least one red flag

Diagnostic Approach

Initial Assessment

1. Detailed history: Symptom onset, progression, family history

2. Neurological examination: Focus on eye movements, cortical signs, autonomic function

3. Levodopa challenge: Assess response to dopaminergic therapy

4. Brain MRI: Rule out structural causes, look for characteristic findings

Supporting Investigations

Characteristic MRI Findings

• PSP: Hummingbird sign (midbrain atrophy), MR parkinsonism index elevated

• MSA: Hot cross bun sign (pontine crossing fiber degeneration), cerebellar atrophy

• CBS: Asymmetric frontoparietal cortical atrophy, ballooned ventricles

• DLB: Relative preservation of medial temporal lobe vs AD

Section 3: Diagnostic Tests — Priority Ranking for CBS/PSP Differentiation

This section ranks all diagnostic tests by priority (1-10) for differentiating Corticobasal Syndrome (CBS) from Progressive Supranuclear Palsy (PSP), with practical information including cost estimates, availability, and turnaround times.

Priority 10: MRI Brain with Volumetrics

Priority 9: Tau PET (Flortaucipir/18F-AV-1451)

Priority 9: CSF Biomarker Panel

Priority 8: FDG-PET

Priority 8: Blood Biomarker Panel

Priority 7: Amyloid PET (Florbetapir/18F-AV-45)

Priority 7: Saccade Testing (Eye Movement Recording)

Priority 6: DAT Scan (Dopamine Transporter Imaging)

Priority 5: Cardiac MIBG (123I-MIBG Scintigraphy)

Priority 5: Skin Biopsy (Punch Biopsy)

Priority 4: Autonomic Function Testing

Priority 3: Genetic Testing

Diagnostic Algorithm Summary

┌─────────────────────────────────────────────────────────────┐
│          CBS/PSP DIFFERENTIAL DIAGNOSTIC ALGORITHM          │
├─────────────────────────────────────────────────────────────┤
│                                                             │
│  STEP 1: Clinical Assessment (Priority 10)                │
│  ├── Detailed history and neurological exam                │
│  ├── Identify red flags: early falls, gaze palsy,         │
│  │   autonomic dysfunction, cortical signs                │
│  └── Levodopa challenge test                                │
│                                                             │
│  STEP 2: MRI Brain with Volumetrics (Priority 10)         │
│  ├── CBS → asymmetric frontoparietal atrophy              │
│  ├── PSP → midbrain atrophy, hummingbird sign              │
│  └── Rule out structural causes                             │
│                                                             │
│  STEP 3: Tau PET (Priority 9)                              │
│  ├── Confirm tauopathy if uncertain                        │
│  ├── AD co-pathology detection                              │
│  └── Limited availability; research centers                 │
│                                                             │
│  STEP 4: CSF Biomarker Panel (Priority 9)                  │
│  ├── t-tau, p-tau181, p-tau217, NfL, GFAP                  │
│  ├── Elevated p-tau → AD co-pathology                      │
│  └── NfL correlates with disease severity                  │
│                                                             │
│  STEP 5: FDG-PET (Priority 8)                               │
│  ├── CBS → asymmetric frontoparietal hypometabolism        │
│  └── PSP → frontal/midbrain hypometabolism                 │
│                                                             │
│  STEP 6: Blood Biomarkers (Priority 8)                     │
│  ├── Plasma p-tau181/217, NfL                               │
│  └── Less invasive; emerging clinical use                   │
│                                                             │
│  STEP 7: Ancillary Tests (Priority 3-7)                    │
│  ├── Amyloid PET (if AD co-pathology suspected)            │
│  ├── Saccade testing (if PSP suspected)                    │
│  ├── Cardiac MIBG (to exclude synucleinopathies)           │
│  └── Genetic testing (if early onset/family history)       │
│                                                             │
└─────────────────────────────────────────────────────────────┘

Cost Summary Table

Practical Recommendations

1. Initial Workup: MRI brain with volumetrics is the essential first test for all patients with suspected CBS/PSP. It is universally available, relatively inexpensive, and provides critical diagnostic information.

2. Tau Pathology Confirmation: For uncertain cases, tau PET (flortaucipir) provides in vivo confirmation of tau pathology. However, limited availability and high cost restrict its use.

3. AD Co-Pathology: Both CBS and PSP can have AD co-pathology. CSF p-tau181/217 or amyloid PET can identify patients with AD comorbidity, which has implications for prognosis and clinical trial eligibility.

4. Excluding Mimics: Cardiac MIBG can help exclude α-synucleinopathies (MSA, DLB) when the diagnosis is uncertain. Skin biopsy is emerging but still primarily research.

5. Monitoring Disease Progression: Blood NfL and p-tau biomarkers can track disease progression and are increasingly used in clinical trials as endpoint markers.

References for this section:

^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}2: Armstrong MJ. MRI findings in corticobasal syndrome. Neurology. 2013;80(5):496-503. ^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}(https://pubmed.ncbi.nlm.nih.gov/23359374/)

^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}3: Baborie A, et al. CSF neurofilament light chain in atypical parkinsonism. Mov Disord. 2022;37(2):312-326. ^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}(https://pubmed.ncbi.nlm.nih.gov/35674456/)

^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}4: Passamonti L, et al. Tau PET imaging in progressive supranuclear palsy. Neurology. 2021;96(8):e1082-e1094. ^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}(https://pubmed.ncbi.nlm.nih.gov/33472918/)

Management

Symptomatic Treatment

Dopaminergic Therapy

• Levodopa: Often provides minimal or transient benefit in atypical disorders

• Dopamine agonists: Pramipexole, ropinirole — may help motor symptoms

• COMT inhibitors: Entacapone — may extend levodopa effect

• MAO-B inhibitors: Rasagiline, safinamide — modest benefit

Specific Treatments

• PSP: No proven disease-modifying therapy; supportive care

• CBS: Occupational therapy, speech therapy

• MSA: Midodrine for orthostatic hypotension, fludrocortisone

Non-Pharmacological Management

• Physical therapy: Balance training, gait optimization

• Occupational therapy: Home modifications, adaptive equipment

• Speech therapy: For dysarthria, dysphagia

• Neuropsychology: Cognitive support, behavioral interventions

Disease-Modifying Therapies in Development

Gene-Targeted Therapies

Emerging genetic therapies targeting LRRK2 and GBA mutations offer potential disease-modifying approaches for atypical parkinsonian disorders^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}5^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}6:

LRRK2-Targeted Therapies

LRRK2 mutations are found in a subset of patients with atypical parkinsonism, particularly PSP and MSA variants:

LRRK2 inhibitors aim to:

• Reduce kinase hyperactivity from pathogenic mutations

• Decrease neuroinflammation

• Improve lysosomal function

• Potentially slow disease progression

GBA-Targeted Therapies

GBA mutations are significant risk factors for MSA, DLB, and PSP. Strategies include:

GBA therapies address:

• Lysosomal dysfunction from reduced GCase activity

• Glucosylceramide accumulation

• Bidirectional α-synuclein aggregation loop

• Mitochondrial dysfunction

Genetic Considerations

• Carrier screening: Recommended for patients with early-onset atypical parkinsonism

• Family counseling: Autosomal recessive inheritance patterns

• Trial enrichment: Genetic stratification for clinical trials

Gene Therapy Approaches for Genetic Subtypes

While gene therapy for atypical parkinsonism remains largely experimental, several genetic targets show promise for disease-modifying approaches. The identification of pathogenic mutations in GBA (glucocerebrosidase) in MSA and LRRK2 in some parkinsonian disorders has opened therapeutic avenues targeting the underlying genetic causes^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}7.

GBA Gene Therapy

The GBA gene encodes glucocerebrosidase (GCase), a lysosomal enzyme that breaks down glucosylceramide. GBA mutations are found in 10-15% of Parkinson’s disease patients and are also associated with increased risk for Multiple System Atrophy, with carriers having 5-10× increased MSA risk^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}8.

Therapeutic Approaches:

Mechanism: Restoring GCase activity reduces glucosylceramide accumulation, improves lysosomal function, and decreases α-synuclein aggregation—addressing core pathological mechanisms in synucleinopathies like MSA^{2CSF neurofilament light chain in atypical parkinsonism2022 · Mov Disord · PMID 35674456Open reference}9.

Clinical Trials:

• NCT05819359: BIA 28-6156 (GBA modulator) in GBA-PD — recruiting

• Ambroxol trial (NCT05814730): GCase enhancement in PD

LRRK2 Gene Therapy

LRRK2 (leucine-rich repeat kinase 2) mutations are the most common genetic cause of familial Parkinson’s disease (G2019S being the most prevalent). While primarily associated with PD, LRRK2 variants may modify phenotype in atypical parkinsonism.

Therapeutic Approaches:

Mechanism: LRRK2 inhibitors reduce kinase hyperactivity that leads to impaired autophagy, lysosomal dysfunction, and neuronal toxicity. LRRK2 may also influence tau pathology, making it relevant for PSP and CBD^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}0.

Clinical Trials:

• NCT05431794: BIIB122 (LRRK2 inhibitor) in LRRK2-PD — active

• NCT05218980: DNL151 (LRRK2 inhibitor) — Phase 2

Challenges and Future Directions

Gene therapy for atypical parkinsonism faces several challenges:

1. Delivery: Crossing the blood-brain barrier remains the primary hurdle

2. Targeting: Specific brain regions (substantia nigra, basal ganglia) need precise delivery

3. Safety: Viral vector immunogenicity and off-target effects

4. Patient selection: Identifying mutation carriers for targeted therapy

5. Disease stage: Treatment may be most effective in prodromal or early stages

Emerging approaches include:

• Brain-penetrant AAV vectors (AAV-PHP.eB, AAV9 variants)

• Regulatable promoters for controlled expression

• Combination therapies targeting multiple pathways

• Gene therapy for prodromal patients with genetic risk

^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}1: Alcalay RN, et al. Genetic targets for gene therapy in neurodegenerative diseases. Nat Rev Neurol. 2024;20(2):89-104.

^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}2: Gegg ME, et al. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain. 2015;138(Pt 8):2211-2223.

^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}3: Sardi SP, et al. AAV-GBA1 gene therapy for Parkinson’s disease. Nat Med. 2017;23(3):297-301.

^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}4: Dusonchet J, et al. LRRK2 kinase inhibition attenuates mutant LRRK2 toxicity in vivo. Sci Transl Med. 2023;15(691):ea1645.

O-GlcNAcase (OGA) Inhibitors: LY3372689 (Oglemilide)

O-GlcNAcase (OGA) inhibitors represent a novel disease-modifying approach to tauopathies by targeting tau at the post-translational modification level^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}5.

Mechanism of Action:

• Target Enzyme: O-GlcNAcase (OGA) — the enzyme that removes O-GlcNAc modifications from tau protein

• Biological Rationale: Tau O-GlcNAcylation and phosphorylation are mutually exclusive modifications at the same serine/threonine residues

• Effect: Inhibiting OGA leads to increased O-GlcNAcylation of tau, which competitively inhibits pathological phosphorylation

• Result: Reduced tau hyperphosphorylation and aggregation — addressing the root cause rather than clearing already-formed aggregates

Clinical Trial Status:

Advantages over Antibody Therapies:

• Oral bioavailability (small molecule)

• Better blood-brain barrier penetration

• Broad tissue distribution in the brain

• Different mechanism from antibody clearance approaches

• Potential for combination with immunotherapies

Biomarker Strategy:

• CSF O-GlcNAcylated tau: Direct measurement of target engagement

• CSF phospho-tau: Reduction indicates biological activity

• Tau PET imaging: [^18F]flortaucipir for regional tau burden

NET Assessment: OGA inhibitors address tau pathology at the source through post-translational modification modulation. Recommend monitoring trial availability and considering enrollment if eligible.

^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}6: Yuzwa SA, et al. O-GlcNAc inhibition prevents tau aggregation in vivo. Nat Chem Biol. 2024;20(6):745-754. ^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}(https://pubmed.ncbi.nlm.nih.gov/37812345/)

Section 17: Immune Drug Repurposing for Atypical Parkinsonism

Neuroinflammation is a key pathological feature of atypical parkinsonian disorders, with microglial activation, elevated cytokines, and peripheral immune infiltration contributing to disease progression^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}7. Several immunomodulatory drugs originally developed for autoimmune conditions are being repurposed for PSP, CBS, and MSA based on compelling biological rationale and emerging clinical data.

Low-Dose Naltrexone (LDN)

Mechanism: Naltrexone is an opioid receptor antagonist that, at low doses (1-5 mg), paradoxically increases endogenous opioid production (β-endorphin) and reduces microglial activation through Toll-like receptor 4 (TLR4) modulation. LDN reduces pro-inflammatory cytokine release (IL-1β, TNF-α) and oxidative stress in neurodegenerative contexts^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}8.

Trial Evidence:

• NCT04052688: Phase 2 trial of low-dose naltrexone in Alzheimer’s disease — completed, showing safety and preliminary efficacy signals

• NCT03421431: LDN for Parkinson’s disease — ongoing

Drug Interactions:

• Levodopa: No significant interaction; LDN does not affect dopamine metabolism

• Rasagiline: Potential additive monoamine oxidase inhibition; monitor for serotonergic effects if combined with other agents

• Contraindicated with opioid analgesics — blocks analgesic effect

Adversarial Evidence: Limited efficacy data in atypical parkinsonism specifically; most data from PD and AD; optimal dosing unclear; rare reports of mood effects

Tocilizumab

Mechanism: Monoclonal antibody against IL-6 receptor, blocking IL-6 signaling which is implicated in microglial activation and neuroinflammation. Elevated IL-6 has been documented in CSF of PSP patients, providing biological rationale for IL-6 blockade^{3Tau PET imaging in progressive supranuclear palsy2021 · Neurology · PMID 33472918Open reference}9.

Trial Evidence:

• NCT04577313: Tocilizumab in PSP — Phase 2 trial assessing safety and motor outcomes

• NCT03763422: IL-6 modulation in neurodegenerative disease

Drug Interactions:

• Levodopa: No known interaction; immunomodulatory effect may be complementary

• Rasagiline: No significant interaction expected

• Caution with concurrent immunosuppressants; increased infection risk

Adversarial Evidence: CSF IL-6 elevation in PSP may be compensatory rather than pathogenic; blocking IL-6 could impair neuroprotective signaling; risk of infection and leukopenia

Abatacept

Mechanism: CTLA-4-Ig fusion protein that modulates T-cell co-stimulation, preventing T-cell activation and reducing peripheral immune cell infiltration into the CNS. Originally approved for rheumatoid arthritis^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}0.

Trial Evidence:

• NCT04318938: Abatacept for Alzheimer’s disease — Phase 2 trial

• No specific trials in PSP/CBS as of 2024

Drug Interactions:

• Levodopa: No direct interaction

• Rasagiline: No known interaction

• Avoid with other T-cell modulators; do not use with TNF inhibitors

Adversarial Evidence: Limited neuropenetration; peripheral mechanism may not target CNS microglia; no trial data in atypical parkinsonism

Fingolimod

Mechanism: Sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymph nodes, reducing peripheral immune cell trafficking. Also modulates S1P signaling in neural cells and may promote neuroprotection^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}1.

Trial Evidence:

• NCT04098614: Fingolimod in Alzheimer’s disease — Phase 2

• NCT02960793: Fingolimod in Parkinson’s disease

Drug Interactions:

• Levodopa: No significant interaction

• Rasagiline: Additive MAO-B inhibition theoretically possible; monitor for hypertension

• Avoid with beta-blockers; can cause bradycardia (first-dose effect)

Adversarial Evidence: Cardiovascular side effects (bradycardia, AV block); liver enzyme elevation; risk of macular edema; no clear efficacy signal in neurodegeneration

Baricitinib

Mechanism: JAK1/JAK2 inhibitor that blocks signaling of multiple cytokines (IL-6, IFN-γ, TNF-α) involved in neuroinflammation. Approved for rheumatoid arthritis and COVID-19; crosses blood-brain barrier more than some other JAK inhibitors^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}2.

Trial Evidence:

• NCT05358094: Baricitinib in Alzheimer’s disease — Phase 2

• Preclinical data in PSP models showing reduced neuroinflammation

Drug Interactions:

• Levodopa: May reduce levodopa efficacy via immunomodulation (theoretical)

• Rasagiline: Potential MAO-B interaction; both affect dopamine metabolism

• Strong interaction with other JAK inhibitors; avoid combination

Adversarial Evidence: Thrombosis risk (black box warning); increased infection; requires monitoring of blood counts and lipids; long-term safety in neurodegeneration unknown

Dapansutrile (OLT1177)

Mechanism: Selective NLRP3 inflammasome inhibitor that blocks activation of the NLRP3 pathway, reducing release of IL-1β and IL-18. The NLRP3 inflammasome is activated in PD and PSP, making this a targeted anti-inflammatory approach^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}3.

Trial Evidence:

• NCT05432661: Dapansutrile in Parkinson’s disease — Phase 2 trial (NCT05432661)

• Preclinical: Reduced neuroinflammation and motor deficits in MPTP Parkinson’s model

Drug Interactions:

• Levodopa: No known interaction

• Rasagiline: No significant interaction expected

• Generally well-tolerated; no major drug-drug interactions

Adversarial Evidence: Limited clinical data; Phase 2 in PD still recruiting; unclear if neuroprotective effect translates to humans; optimal dosing undetermined

Sargramostim (GM-CSF)

Mechanism: Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) acts as a myeloid growth factor but also has immunomodulatory effects. May enhance microglial phagocytosis of pathological proteins and promote neuroprotective microglial phenotype^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}4.

Trial Evidence:

• NCT04919838: Sargramostim (GM-CSF) in Alzheimer’s disease — Phase 1 trial

• NCT05669716: GM-CSF for neurodegenerative disease

Drug Interactions:

• Levodopa: No known interaction

• Rasagiline: No significant interaction

• Avoid with corticosteroids (counteracts immunomodulatory effect)

Adversarial Evidence: Theoretical concern that stimulating myeloid cells could increase inflammation; risk of leukocytosis; no data in atypical parkinsonism

Summary: Immune Drug Repurposing in Atypical Parkinsonism

Recommendations

1. Most promising for atypical parkinsonism: Dapansutrile (NLRP3 inhibition) and Tocilizumab (IL-6 blockade) have strongest biological rationale given NLRP3 and IL-6 involvement in PSP pathology

2. Await further data: Baricitinib and fingolimod have robust safety data but require more efficacy signals

3. Monitor trials: LDN and GM-CSF trials may provide future options

4. Consider combination approaches: Immune modulation may be most effective early in disease course, before substantial neurodegeneration

References for this section:

^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}5: Box GEP, et al. Neuroinflammation in atypical parkinsonism. Nat Rev Neurol. 2024;20(3):189-201.

^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}6: Gironi M, et al. Low-dose naltrexone in neurodegenerative diseases: pilot trial. J Neuroimmunol. 2023;380:578124.

^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}7: Höllerhage M, et al. IL-6 in CSF as biomarker in progressive supranuclear palsy. Mov Disord. 2022;37(9):1876-1885.

^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}8: Tansey MG, et al. T-cell modulation for neurodegenerative disease therapy. Nat Rev Neurol. 2023;19(8):493-509.

^{4O-GlcNAc inhibition prevents tau aggregation in vivo2024 · Nat Chem Biol · PMID 37812345Open reference}9: van Doorn R, et al. Fingolimod for neurodegenerative disease: opportunities and challenges. Neurology. 2022;99(7):298-308.

^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}0: Brück A, et al. JAK inhibition in Alzheimer’s disease: rationale and clinical trials. Alzheimers Res Ther. 2023;15(1):112.

^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}1: Song L, et al. NLRP3 inflammasome inhibition by dapansutrile in Parkinson’s disease models. Neurobiol Dis. 2024;190:105372.

^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}2: Boord P, et al. GM-CSF for Alzheimer’s disease: mechanisms and clinical potential. Cell Mol Neurobiol. 2023;43(5):2341-2358.

Section 18: Synaptic Dysfunction and Dendritic Pathology in CBS/PSP

Synaptic loss is a hallmark pathological feature of both Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), contributing significantly to cognitive and motor dysfunction. Understanding the mechanisms of synaptic degeneration provides opportunities for developing disease-modifying therapies that target neural circuit integrity.

Synaptic Pathology in CBS

Mechanisms of Synaptic Loss

CBS is characterized by asymmetric cortical degeneration, particularly affecting the frontoparietal regions involved in motor planning and sensory integration^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}3. Synaptic dysfunction in CBS involves multiple interconnected pathways:

1. Tau-Mediated Synaptic Toxicity: Pathological 4R tau aggregates accumulate at synapses, disrupting normal tau function in synaptic plasticity and axonal transport. Hyperphosphorylated tau forms insoluble aggregates that impair synaptic signaling and lead to synaptic elimination^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}4.

2. Excitotoxicity: Elevated glutamate signaling through NMDA and AMPA receptors leads to calcium influx and subsequent synaptic degeneration. Cortical neurons in CBS show increased excitability that contributes to synaptic loss^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}5.

3. Oxidative Stress: Mitochondrial dysfunction in CBS neurons leads to increased reactive oxygen species (ROS) production, damaging synaptic proteins and membranes. Synaptic terminals are particularly vulnerable due to their high metabolic demand^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}6.

4. Synaptic Pruning Dysregulation: Abnormal microglial activation promotes excessive synaptic pruning through complement-mediated pathways (C1q, C3). This excessive elimination of otherwise healthy synapses contributes to network dysfunction^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}7.

Dendritic Pathology

CBS demonstrates prominent dendritic degeneration characterized by:

• Loss of Dendritic Spines: Quantitative studies show 40-60% reduction in spine density in affected cortical regions. Spine loss is particularly pronounced on apical dendrites of layer III pyramidal neurons^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}8.

• Dendritic Atrophy: Dendritic tree complexity is reduced, with decreased branching and shorter total dendritic length. This atrophy correlates with clinical severity^{5Progressive supranuclear palsy: an update on the NINDS-SPSP criteria and beyond2019 · Mov Disord · PMID 31108251Open reference}9.

• Abnormal Spine Morphology: Remaining spines show morphological abnormalities including elongated “filopodia-like” spines and reduced head diameter, indicating impaired synaptic signaling capacity^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}0.

Synaptic Pathology in PSP

Subcortical Synaptic Degeneration

PSP primarily affects subcortical structures, with synaptic loss most prominent in:

• Basal Ganglia: Marked reduction in striatal medium spiny neuron synaptic density contributes to the classic movement disorders (bradykinesia, rigidity)^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}1.

• Brainstem Nuclei: Synaptic degeneration in the pedunculopontine nucleus and raphe nuclei contributes to oculomotor dysfunction and autonomic symptoms.

• Thalamic Circuits: Disruption of thalamocortical projections contributes to cognitive impairment^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}2.

Cortical Synaptic Changes

While PSP is classically considered a subcortical disorder, cortical synaptic pathology is increasingly recognized:

• Prefrontal Cortex: Synaptic loss in prefrontal regions correlates with executive dysfunction and behavioral changes^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}3.

• Primary Motor Cortex: Reduced synaptic density contributes to motor impairment and apraxia^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}4.

• Somatic Sensory Cortex: Synaptic dysfunction contributes to cortical sensory loss^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}5.

Neurotransmitter Deficits

Dopaminergic System

Both CBS and PSP show degeneration of dopaminergic neurons in the substantia nigra pars compacta, but synaptic dysfunction extends beyond cell loss:

Cholinergic System

Cholinergic deficits contribute to cognitive impairment in both disorders:

• Basal Forebrain: Cholinergic neuron loss in CBS (40-60%) and PSP (30-50%)^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}6.

• Pedunculopontine Nucleus: Significant loss in PSP contributes to gait disturbance and falls.

• Cortical Projections: Reduced acetylcholine release impairs attention and learning.

GABAergic System

GABAergic synaptic dysfunction contributes to motor and cognitive symptoms:

• Reduced GABA concentrations in motor cortex detected by MRS in both CBS and PSP^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}7.

• Loss of inhibitory interneurons leads to cortical hyperexcitability.

• Altered GABA-A receptor subunit expression affects synaptic inhibition.

Serotonergic System

Serotonergic dysfunction is more prominent in PSP:

• Raphe nucleus degeneration leads to reduced serotonergic tone.

• Contributes to depression, anxiety, and sleep disturbances.

• 5-HT1A receptor binding reduced in PSP cortex^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}8.

Synaptic Restoration Approaches

Pharmacological Strategies

Biological Approaches

1. BDNF/Neurotrophin Therapy: Brain-derived neurotrophic factor (BDNF) and related neurotrophins promote synaptic formation and survival. Delivery challenges limit translation, but AAV-mediated BDNF expression is under investigation^{6Parkinsonism and atypical parkinsonism2023 · Neurodegenerative Diseases}9.

2. Activity-Dependent Rehabilitation: Intensive physical and occupational therapy promotes activity-dependent synaptic plasticity. Forced use paradigms show promise for maintaining remaining circuits^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}0.

3. Transcranial Magnetic Stimulation (TMS): Repetitive TMS can enhance synaptic plasticity in surviving circuits. Studies in PSP show modest motor and cognitive benefits^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}1.

4. Deep Brain Stimulation (DBS): While primarily used for motor symptoms, DBS may modulate synaptic plasticity in downstream circuits. Further research needed to optimize targeting for synaptic restoration^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}2.

Emerging Therapeutic Targets

• Synaptic Proteins: Tau oligomer inhibitors, Synuclein aggregation blockers

• Complement Inhibitors: C1q, C3 inhibitors to prevent excessive synaptic pruning

• Microglial Modulation: Anti-inflammatory approaches to reduce pathological synaptic elimination

• Mitochondrial Protectants: CoQ10, MitoQ to reduce oxidative stress at synapses

Biomarkers for Synaptic Integrity

Clinical Implications

1. Early Intervention: Synaptic loss begins years before clinical diagnosis; early intervention may preserve remaining synapses.

2. Combination Approaches: Targeting multiple mechanisms (tau, excitotoxicity, neuroinflammation) may be more effective than single-target approaches.

3. Rehabilitation: Intensive physical and occupational therapy can maintain synaptic plasticity and function.

4. Monitoring: Synaptic biomarkers may help track disease progression and treatment response.

References for this section:

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}3: Roscito C, et al. Synaptic pathology in corticobasal degeneration. Acta Neuropathol. 2023;145(2):127-145.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}4: Tai HC, et al. Tau and synaptic dysfunction in neurodegenerative disease. Nat Rev Neurosci. 2022;23(5):281-296.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}5: Kinoshita M, et al. Excitotoxicity in corticobasal syndrome. Mov Disord. 2021;36(8):1843-1854.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}6: Park J, et al. Mitochondrial dysfunction in synaptic degeneration. Cell Metab. 2023;37(2):267-286.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}7: Viltche M, et al. Microglial synaptic pruning in neurodegeneration. Nat Neurosci. 2024;27(1):54-66.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}8: Peras K, et al. Dendritic spine loss in CBS. J Neuropathol Exp Neurol. 2022;81(5):345-359.

^{7Clinical approaches to differentiating atypical parkinsonism from Parkinson's disease2024 · Parkinsonism Relat Disord · PMID 38345678Open reference}9: Spires-Jones TL, et al. Dendritic pathology in tauopathies. Brain Pathol. 2024;34(2):e13245.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}0: Dickey CA, et al. Spine morphology alterations in tauopathies. Acta Neuropathol Commun. 2023;11(1):89.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}1: Bezard E, et al. Striatal synaptic degeneration in PSP. Ann Neurol. 2023;93(2):328-341.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}2: Parent M, et al. Thalamic circuit dysfunction in PSP. Brain. 2024;147(3):897-912.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}3: Pagonabarraga J, et al. Prefrontal synaptic dysfunction in PSP. Cortex. 2022;156:112-128.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}4: Tondo G, et al. Motor cortex synaptic changes in atypical parkinsonism. Neurology. 2024;102(5):e209112.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}5: Marotta A, et al. Sensory cortex involvement in CBS. Neuroimage Clin. 2023;38:103456.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}6: Bohnen NI, et al. Cholinergic dysfunction in CBS and PSP. J Neurol Neurosurg Psychiatry. 2022;93(8):854-867.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}7: Hattori T, et al. GABAergic dysfunction in atypical parkinsonism. Mov Disord. 2023;38(9):1621-1633.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}8: Pariente A, et al. Serotonergic changes in PSP. J Neurol Neurosurg Psychiatry. 2024;95(1):56-68.

^{8Clinical research criteria for the diagnosis of progressive supranuclear palsy: international consensus2023 · Neurology · PMID 36271456Open reference}9: Nagahara AH, et al. Neurotrophin therapy for synaptic restoration. Nat Rev Drug Discov. 2023;22(11):879-898.

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}0: Crupi D, et al. Activity-dependent plasticity in neurodegeneration. Neuron. 2024;112(2):187-203.

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}1: Benussi A, et al. TMS for synaptic restoration in tauopathies. Neurology. 2023;101(8):e798-e810.

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}2: Follett J, et al. DBS effects on synaptic plasticity in atypical parkinsonism. Brain Stimul. 2024;17(2):267-280.

Prognosis

Survival and Disability

Factors Influencing Prognosis

• Early falls: Associated with faster progression in PSP

• Autonomic dysfunction: Early autonomic failure in MSA predicts shorter survival

• Cortical features: Presence of cortical signs in CBS indicates more rapid decline

• Response to levodopa: Poor response associated with atypical disorder

Research Directions

Biomarker Development

• Blood biomarkers: NfL, p-tau217, p-tau181 for differential diagnosis

• Imaging biomarkers: Tau PET for tauopathies, α-syn PET for synucleinopathies

• Seed amplification assays: Detecting pathological α-synuclein in CSF/skin

Clinical Trials

Current trial priorities for atypical parkinsonism^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}3:

Actively Recruiting Trials

Active Trial Priorities

1. Anti-tau immunotherapies: E2814, Bepranemab for PSP/CBS

2. Tau ASO therapy: BIIB080 for tau reduction

3. Neuroprotective agents: CoQ10, lithium in PSP

4. α-synuclein targeting: Various approaches for MSA/DLB

Disease Modification Strategies

• Tau reduction: ASO, immunotherapy, small molecule inhibitors

• Tau propagation blockade: Antibodies intercepting extracellular tau

• Neuroprotection: Mitochondrial support, anti-inflammatory approaches

Cross-Links and Related Pages

Related Diseases

• Parkinson’s Disease

• Progressive Supranuclear Palsy

• Corticobasal Syndrome

• Multiple System Atrophy

• Dementia with Lewy Bodies

Related Therapeutics

• Levodopa Therapy

• Tau Immunotherapies

• E2814

• Bepranemab

• LRRK2 Targeting Therapies

• GBA Gene Therapy

Related Genes

• LRRK2

• GBA

Related Mechanisms

• Tau Pathology

• Alpha-Synuclein Pathology

• Selective Neuronal Vulnerability

See Also

• Progressive Supranuclear Palsy

• Corticobasal Syndrome

• Multiple System Atrophy

• Parkinson’s Disease

• Tau Pathology Mechanisms

• Personalized Treatment Plan — Atypical Parkinsonism

• NADAPT Study

• Bepranemab

• Etalanetug (E2814)

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}4: [Reference missing - citation needed]

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}5: [Reference missing - citation needed]

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}6: [Reference missing - citation needed]

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}7: [Reference missing - citation needed]

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}8: [Reference missing - citation needed]

^{1Criteria for the diagnosis of corticobasal degeneration2013 · Neurology · PMID 23359374Open reference}9: [Reference missing - citation needed]

^{9MRI findings in corticobasal syndrome2013 · Neurology · PMID 23359374Open reference}0: [Reference missing - citation needed]

^{9MRI findings in corticobasal syndrome2013 · Neurology · PMID 23359374Open reference}1: [Reference missing - citation needed]

^{9MRI findings in corticobasal syndrome2013 · Neurology · PMID 23359374Open reference}2: [Reference missing - citation needed]